U.S. Markets open in 1 hr 27 mins

Should You Take Comfort From Insider Transactions At CorMedix, Inc. (NYSEMKT:CRMD)?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might well want to know whether insiders have been buying or selling shares in CorMedix, Inc. (NYSEMKT:CRMD).

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, such insiders must disclose their trading activities, and not trade on inside information.

We don't think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.'

See our latest analysis for CorMedix

The Last 12 Months Of Insider Transactions At CorMedix

In the last twelve months, the biggest single purchase by an insider was when Head of Human Resources & Executive VP of Technical Operations John Armstrong bought US$363k worth of shares at a price of US$7.26 per share. So it's clear an insider wanted to buy, at around the current price, which is US$7.53. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider purchases were made at close to current prices.

Over the last year, we can see that insiders have bought 123k shares worth US$872k. CorMedix may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

AMEX:CRMD Recent Insider Trading, May 8th 2019

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insiders at CorMedix Have Bought Stock Recently

Over the last quarter, CorMedix insiders have spent a meaningful amount on shares. Not only was there no selling that we can see, but they collectively bought US$187k worth of shares. This could be interpreted as suggesting a positive outlook.

Does CorMedix Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Based on our data, CorMedix insiders have about 2.0% of the stock, worth approximately US$3.5m. We consider this fairly low insider ownership.

What Might The Insider Transactions At CorMedix Tell Us?

It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that CorMedix insiders are reasonably well aligned, and optimistic for the future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for CorMedix.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.